FDA Clears Portable Incubator to Bridge US Neonatal Care Gaps

NOTTINGHAM, England – January 21, 2026 – In a move poised to reshape neonatal care across the United States, mOm Incubators Limited announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its mOm Essential Incubator. The clearance allows the company to market its first-of-its-kind portable incubator, a device designed to provide critical thermoregulation for premature babies, opening a significant new market for the UK-based innovator.

This novel device is engineered for versatility, enabling it to be used in a wide array of healthcare settings. Its core mission is to prevent neonatal hypothermia, a common and dangerous condition for preterm infants, while allowing newborns to remain close to their mothers. This approach aims to reduce parental stress, promote essential bonding, and ultimately improve health outcomes for some of the nation's most vulnerable patients.

Addressing a Critical Gap in American Healthcare

The FDA's decision comes at a crucial time for maternal and infant health in the United States. The country, which sees approximately 400,000 premature births each year, is grappling with growing disparities in healthcare access. A 2022 March of Dimes report revealed that over a third of U.S. counties—more than 1,100 in total—are classified as 'maternity care deserts,' lacking any hospitals with obstetric services, birth centers, or obstetric providers. This reality affects nearly seven million women and over half a million births annually.

The problem is particularly acute in rural and semi-urban areas, which have witnessed a steady closure of hospital obstetric units over the last decade. For families in these regions, the birth of a premature baby often triggers an immediate and traumatic separation. Lacking the specialized equipment and staff of a Neonatal Intensive Care Unit (NICU), local hospitals are forced to transfer these fragile newborns, sometimes hundreds of miles away, to tertiary care centers. These transfers are not only costly but also place immense emotional and financial strain on families.

“The U.S. has experienced a wave of closures of neonatal care units over the last 15 years, and this has made high-quality care for premature babies more difficult to access,” said Anne Groves, M.D., a Consultant Neonatologist and Founder of AEG Innovations. “The mOm incubator offers an innovative way to address a key gap for labor and delivery units in many rural and semi-urban hospitals, by reducing the number of babies that need to be moved — sometimes long distances—to a NICU, and by avoiding the trauma of separating mother and baby.”

A New Paradigm in Neonatal Thermoregulation

The mOm Essential Incubator is designed to directly challenge the traditional, stationary model of neonatal care. Unlike the large, complex, and expensive incubators that are fixtures in Level III and IV NICUs, the mOm device is compact, lightweight, and engineered for portability. It can operate on multiple power sources and includes a backup battery that can maintain a stable temperature for at least one hour, ensuring continuous care during intra-hospital movement or power fluctuations.

This flexibility allows the incubator to be deployed 'anywhere and everywhere'—from a standard labor and delivery room to a post-natal ward or an emergency stabilization area. By providing effective thermoregulation at the point of birth, the device empowers smaller hospitals to safely care for late preterm and term infants at risk of hypothermia, potentially avoiding the need for an immediate transfer. This capability is central to the company's vision of patient-centered care.

“Since we first started deploying the mOm Essential Incubator into labor and delivery settings, it has been incredibly gratifying to see the impact of this device in reducing complications and improving babies’ lives, and at the same time keeping parents closer to their newborn, which ultimately is what every parent wants when they bring a new life into the world,” said James Roberts, CEO and inventor of the device. “Becoming commercially available in the U.S. is a major step towards more widespread adoption of our technology.”

Proven Impact Beyond US Borders

While new to the U.S., the mOm Essential Incubator has already built a strong track record in Europe and globally. The device received its MDR (EU) CE mark in 2022 and has since been implemented in multiple National Health Service (NHS) hospitals across the United Kingdom. There, it has been used to help maintain the core temperature of babies being moved around hospital sites and to reduce short-term admissions to special care units for hypothermia.

The results have been striking. A recent Quality Improvement project at Liverpool Women’s Hospital, for example, showed that hypothermia admissions to the NICU dropped to zero following the implementation of mOm Incubators. Other sites reported a reduced incidence of respiratory distress in newborns while successfully keeping families together, promoting bonding, and improving the overall patient experience.

Beyond established healthcare systems, the incubator's robust and adaptable design has also made it a vital tool in humanitarian emergencies and conflict zones, where it is being used to save the lives of premature babies in the most challenging environments imaginable.

“The mOm Essential Incubator is a highly versatile innovation, capable of delivering improvements in clinical outcomes in established healthcare systems as well as saving babies’ lives in underresourced economies and areas impacted by armed conflict,” noted Joshua Boger, Ph.D., a Member of the Board of Directors of mOm Incubators Limited. He highlighted its potential to have a “transformational impact” in the U.S. by increasing care access in rural areas and reducing NICU admissions.

The Economic and Human Equation

The introduction of the mOm Essential Incubator into the U.S. market carries significant financial and human implications. For hospitals, particularly smaller rural facilities operating on thin margins, the economic calculus is compelling. The cost of a single neonatal emergency transport can run into thousands, or even tens of thousands, of dollars. By enabling local stabilization and reducing the number of necessary transfers, the device offers a clear path to substantial cost savings.

This aligns with the broader healthcare industry’s shift toward value-based care models, which prioritize cost-effective interventions that improve patient outcomes. The incubator represents a lower capital investment than a full NICU bay, making it an accessible solution for facilities looking to enhance their neonatal capabilities without a complete infrastructure overhaul.

Ultimately, however, the device's greatest value may lie in its human impact. By preventing the immediate separation of mother and child, it supports the foundational principles of family-centered care and infant bonding, which are known to have long-term developmental benefits. For parents facing the anxiety of a premature birth, the ability to stay by their infant’s side is invaluable. For countless families and the hospitals that serve them, this small device promises to make a world of difference.